Skip to main content

CV and Cancer Risk with JAK inhibitors

Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×